Trinity Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	43.79	61.56	56.83	62.52	81.15
Revenue Growth	-28.87%	8.31%	-9.10%	-22.96%	-20.43%
Cost of Revenue	26.9	40.11	37.38	45.25	47.7
Gross Profit	16.89	21.44	19.45	17.27	33.45
Selling, General & Admin	24.67	28.82	31.15	26.98	22.5
Research & Development	3.63	4.54	4.38	4.14	4.5
Other Operating Expenses	-1.87	1.79	-0.14	-0.34	-0
Operating Expenses	26.43	35.15	35.39	30.78	27
Operating Income	-9.55	-13.7	-15.94	-13.51	6.46
Interest Expense	-12.81	-11.91	-10.15	-11.53	-7.09
Interest & Investment Income	-	-	1.17	-	0
Other Non Operating Income (Expenses)	-0.2	-1.17	-	0.23	1.22
EBT Excluding Unusual Items	-22.55	-26.78	-24.92	-24.81	0.6
Merger & Restructuring Charges	-4.25	-4.18	-	-	-
Impairment of Goodwill	-2.14	-1.6	-5.83	-	-3.85
Gain (Loss) on Sale of Investments	-	0.8	-1.5	-	-
Asset Writedown	-0.03	-0.61	-3.77	-5.36	-2.51
Other Unusual Items	-8.19	1.64	-0.91	-13.61	3.84
Pretax Income	-37.18	-30.73	-36.93	-43.78	-1.92
Income Tax Expense	0.2	0.49	-0.06	-0.19	-0.07
Earnings From Continuing Operations	-37.38	-31.22	-36.87	-43.59	-1.85
Earnings From Discontinued Operations	-	-0.57	12.85	2.58	2.73
Net Income	-37.38	-31.79	-24.02	-41.01	0.88
Net Income to Common	-37.38	-31.79	-24.02	-41.01	0.88
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	1	1	0	0	0
Shares Outstanding (Diluted)	1	1	0	0	0
Shares Change	3.43%	134.61%	13.46%	61.40%	-
EPS (Basic)	-60.36	-53.10	-94.13	-182.34	6.28
EPS (Diluted)	-60.36	-60.96	-94.13	-182.34	6.28
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-6.02	-4.6	-12.36	-2.02	11.43
Free Cash Flow Per Share	-9.72	-7.68	-48.44	-8.99	82.00
Gross Margin	38.57%	34.83%	34.22%	27.62%	41.23%
Operating Margin	-21.80%	-22.26%	-28.05%	-21.61%	7.96%
Profit Margin	-85.36%	-51.64%	-42.26%	-65.59%	1.08%
Free Cash Flow Margin	-13.74%	-7.47%	-21.75%	-3.23%	14.08%
EBITDA	-8.24	-13.03	-14.17	-11.22	9.18
EBITDA Margin	-18.83%	-21.17%	-24.92%	-17.94%	11.31%
D&A For EBITDA	1.3	0.68	1.78	2.29	2.72
EBIT	-9.55	-13.7	-15.94	-13.51	6.46
EBIT Margin	-21.80%	-22.26%	-28.05%	-21.61%	7.96%

SEC Filings: 10-K · 10-Q